http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107056947-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-09 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2497 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y305-04001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y302-02027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-78 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107056947-B |
| titleOfInvention | anti-HBV replication targeted fusion protein and construction method thereof |
| abstract | The invention relates to a targeted fusion protein for resisting HBV replication and a construction method thereof. The peptide fragment is used as a guide molecule of targeting cccDNA and is marked as HBc144 by utilizing the characteristic that the C-terminal region (CTD) of the hepatitis B virus core protein HBc can be specifically combined with HBV cccDNA; synthesizing an A3A-HBc144 coding gene sequence and an HBc144-UNG2 coding gene sequence, cloning the two sequences to multi-cloning sites MCS1 and MCS2 of a eukaryotic expression vector pVITRO2-neo-MCS to construct a recombinant dual expression vector Pvitro2-A3A-HBc/HBc-UNG2, wherein the recombinant vector can simultaneously express two fusion proteins, namely A3A-HBc144 and HBc144-UNG2, in liver cells, the invention realizes the targeting of A3A and UNG2 to HBV cccDNA, and has stronger effect of inhibiting virus replication compared with a vector which independently expresses A3A or A3A-HBc. |
| priorityDate | 2016-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 467.